Key result
Pulmonary vasodilators and statins show promise in COPD patients with moderate-to-severe pulmonary hypertension.
Why the study?
Do pulmonary vasodilators and statins improve outcomes in patients with pulmonary hypertension secondary to COPD?
Do pulmonary vasodilators and statins improve outcomes in patients with pulmonary hypertension secondary to COPD?
This review highlights the potential role of targeted pulmonary vasodilator therapy and statins in a specific subset of COPD patients with moderate to severe pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
May support targeted therapy in select moderate-severe COPD-PH; leaves open confirmation by prospective RCTs.
The development of pulmonary hypertension in COPD adversely affects survival and exercise capacity and is associated with an increased risk of severe acute exacerbations. Unfortunately not all patients with COPD who meet criteria for long term oxygen therapy benefit from it. Even in those who benefit from long term oxygen therapy, such therapy may reverse the elevated pulmonary artery pressure but cannot normalize it. Moreover, the recent discovery of the key roles of endothelial dysfunction and inflammation in the pathogenesis of PH provides the rationale for considering specific pulmonary vasodilators that also possess antiproliferative properties and statins.
No takes yet. Share an insight, caveat, or question.
Shujaat et al. (2012) conducted a review in Pulmonary Hypertension Secondary to COPD. Pulmonary vasodilators and statins was evaluated. Pulmonary vasodilators and statins show promise for treating pulmonary hypertension secondary to COPD in patients with moderate to severe PH (mPAP > 25 mm Hg) without severe hyperinflation.
Synapse has enriched 10 related papers. Consider them for comparative context: